9 mg/ml
Sponsors
Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A., Lipigon Pharmaceuticals AB, Medical University Of Gdansk, Nicolaus Copernicus University, AstraZeneca AB
Conditions
Breathing disorders as a cause of neonatal respiratory failureCOVID-19 and other pulmonary parenchyma infections.Diabetic foot ulcers infected by Acinetobacter baumanniiHeart failure with reduced ejection fractionModerate to severe hypertriglyceridemiaPseudomonas aeruginosa and /or Staphylococcus aureusRecent myocardial infarction associated with iron deficientRenal impairment
Phase 1
Evaluation of treatment effectiveness and safety of somatic cell based therapy for urinary incontinence in patients after radical prostatectomy, multicenter randomized, double-blind, placebo controlled, clinical trial.
WithdrawnCTIS2023-509812-27-00
Target: 45Updated: 2024-04-08
A Phase 1b, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)
CompletedCTIS2024-513143-82-00
Start: 2024-10-15End: 2025-08-21Target: 12Updated: 2025-02-11
Phase 2
A Phase 2b Clinical Study to Evaluate the Safety and Efficacy of Topical Administration of
Bacteriophage Therapy TP-102 in Patients with Diabetic Foot Infection
CompletedCTIS2023-507716-13-00
End: 2025-12-19Target: 26Updated: 2025-08-18
A phase 2, randomised, double-blind, placebo-controlled trial to evaluate safety and local tolerability of four weekly administrations of A24110He in subjects with elevated triglyceride plasma concentrations
CompletedCTIS2023-509091-42-00
Start: 2024-02-27End: 2026-01-08Target: 26Updated: 2025-07-04
Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of nandrolone decanoate therapy and therapy with complex physiotherapy and diet in the treatment of sarcopenia
RecruitingCTIS2024-517178-48-00
Start: 2023-03-15Target: 168Updated: 2024-10-31
ITPP as an adjunctive treatment for progressive respiratory failure in COVID-19 and other pulmonary parenchymal infections - a randomized, double-blind, non-commercial phase II clinical trial [BREATH2]
CompletedCTIS2024-517878-21-00
Start: 2023-11-28End: 2025-06-11Target: 100Updated: 2025-02-10
Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab – a randomized head to head study
WithdrawnCTIS2025-523714-92-00
Target: 80Updated: 2025-12-15
Phase 3
Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions (STOP CLOT Trial)
Not yet recruitingCTIS2024-516376-15-00
Target: 410Updated: 2025-05-16
Evaluation of frequency occurrence persistent pulmonary hypertension of newborns in group of newborns born between 32 and 42 weeks of pregnancy treated by salbutamol
CompletedCTIS2024-515216-46-00
Start: 2021-11-15End: 2025-11-04Target: 608Updated: 2024-12-16
The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement
RecruitingCTIS2023-509111-89-00
Start: 2025-10-15Target: 66Updated: 2025-06-30